Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and

Novartis trims again with $390m drugs sale to Recordati

Novartis and Amgen axe BACE drug for Alzheimer's

Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.

FDA fast tracks Prevail's Parkinson's gene therapy

The FDA has fast tracked a gene therapy for a certain form of Parkinson’s Disease from US biotech Prevail Therapeutics.

ViiV hails data showing switch from Truvada to two-drug HIV ...

ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors confidence that patients can switch from rival triple therapies to its new two-drug

Bayer/J&J eye new paediatric use for anticoagulant Xarelto

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagul